Publicaciones en colaboración con investigadores/as de Stony Brook University (5)

2022

  1. Role of EXO1 nuclease activity in genome maintenance, the immune response and tumor suppression in Exo1D173Amice

    Nucleic Acids Research, Vol. 50, Núm. 14, pp. 8093-8106

2021

  1. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

    Future Oncology, Vol. 17, Núm. 11, pp. 1295-1310

2020

  1. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

    The Lancet Haematology, Vol. 7, Núm. 7, pp. e511-e522

2019

  1. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas

    Blood, Vol. 133, Núm. 22, pp. 2401-2412

2012

  1. IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions

    Blood, Vol. 120, Núm. 24, pp. 4802-4811